In vitro models

Primary cell cultures
Cancer cell lines (lymphoma, glioblastoma, breast cancer, colon cancer, lung cancer and other customizable models).
Tissue cultures
Injury models

In vitro screening assays

Immunophenotyping
Gene expression profiling (mRNA)
microRNA profiling (miRNA)
Transcribed ultraconserved non-conding RNA profiling (T-UCRs)
Proliferation assays
Cellular functional profiling (ELISPOT/FLUOROSPOT analysis)

ask an expert

In vivo models

Cell line-derived xenograft models (CDX)
Syngeneic mouse models
Patient-derived xenograft models (PDX)
Metastasis models

In vivo services

Pharmacokinetics
Toxicity studies
Histopathology
Metastasis evaluation

Chimeric Antigen Receptor-T cell therapy R&D services

Chimeric antigen receptor T (CAR-T) cell technology has revolutionized cancer treatment. This technology redirects T cell immune response towards malignant cells, mediating tumor cell death. By engineering specific antigen receptors in patient/donor T cells, it is possible to create personalized and unlimited treatment options for various types of cancer.

CAR-T design/expression/function assessment
CAR-T Activation
CAR-T Specificity
CAR-T Cytotoxicity in target and non-target cells
CAR-T Exhaustion

Immuno-oncology

Chimeric Antigen Receptor-T cell therapy R&D services

Services

Contacts